<SEC-DOCUMENT>0001231919-25-000494.txt : 20251114
<SEC-HEADER>0001231919-25-000494.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114162855
ACCESSION NUMBER:		0001231919-25-000494
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jade Biosciences, Inc.
		CENTRAL INDEX KEY:			0001798749
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831377888
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92668
		FILM NUMBER:		251486972

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		(781) 312-3013

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aerovate Therapeutics, Inc.
		DATE OF NAME CHANGE:	20200103

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frazier Life Sciences Public Fund, L.P.
		CENTRAL INDEX KEY:			0001863769
		ORGANIZATION NAME:           	
		EIN:				862999645
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		650-325-5156

	MAIL ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
		<previousAccessionNumber>0001415889-25-011894</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001863769</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>2</amendmentNo>
	      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001798749</issuerCik>        <issuerName>JADE BIOSCIENCES, INC.</issuerName>        <issuerCusip>008064206</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>930 WINTER STREET</com:street1>
          <com:street2>SUITE M-500</com:street2>          <com:city>WALTHAM</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02451</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1384646.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1384646.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1384646.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>4.2</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1384646.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1384646.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1384646.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>4.2</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1384646.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1384646.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1384646.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>4.2</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>9488.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>9488.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>9488.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>9488.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>9488.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>9488.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>9488.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>9488.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>9488.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>19146.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>19146.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>19146.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.1</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>19146.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>19146.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>19146.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.1</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>19146.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>19146.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>19146.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.1</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James N. Topper</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>9488.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>9488.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>9488.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of 9,488 shares of Common Stock held directly by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Patrick J. Heron</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>9488.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>9488.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>9488.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of 9,488 shares of Common Stock held directly by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 32,626,730 shares of Common Stock outstanding on August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>JADE BIOSCIENCES, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>930 WINTER STREET, SUITE M-500, WALTHAM, MA, 02451.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The entities and persons filing this statement (collectively, the "Reporting Persons") are:

Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron" and together with Topper, the "Members")</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address of the principal place of business for each of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
</principalBusinessOfficeOrResidenceAddress>        <citizenship>The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference.

FLSPF directly holds 1,384,646 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.

FLS X directly holds 9,488 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.

FLS XI directly holds 19,146 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.

Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.</amountBeneficiallyOwned>    <classPercent>The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>

            <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>

    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 99.1 Joint Filing Agreement</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C. </title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C. </title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C. </title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James N. Topper</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Patrick J. Heron</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>


    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99-11142025_091158.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-99-11142025_091158.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px" align="right"><b>EXHIBIT 99.1</b></p>
<p style="margin:0px" align="right"><br></p>
<p style="margin:0px" align="center"><b>JOINT FILING AGREEMENT</b></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:48px" align="justify">Pursuant to Rule&nbsp;13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule&nbsp;13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Jade Biosciences, Inc.</p>
<p style="margin:0px; text-indent:48px" align="justify">&nbsp;</p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
<hr style="margin-bottom: 9.6px; padding-top: 9.6px;" noshade size="1"><p style="page-break-before:always;margin-top:0;margin-bottom:-4pt;font-size:4pt"></p><p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">James N. Topper</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Patrick J. Heron</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Steve R. Bailey, as Attorney-in-Fact</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">*This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
